Citation

Isaacs D, Esterly JS. U.S. Pharmacist 2011; 36(8): HS17-HS26.

Copyright

(Copyright © 2011)

DOI

unavailable

PMID

unavailable

Abstract

[Abstract unavailable]

Language: en

Keywords

human; nephrotoxicity; insomnia; abdominal pain; depression; suicide attempt; kidney failure; lamivudine; fatigue; article; treatment planning; serology; unclassified drug; patient monitoring; Human immunodeficiency virus infection; neutropenia; thrombocytopenia; headache; treatment indication; anxiety disorder; nonhuman; drug choice; drug safety; interferon; recombinant alpha2b interferon; long term care; drug efficacy; diarrhea; drug tolerability; nausea; leukopenia; drug withdrawal; hepatitis C; irritability; lymphocytopenia; side effect; hyperuricemia; anemia; flu like syndrome; Hepatitis C virus; myalgia; pruritus; ribavirin; muscle weakness; myopathy; peripheral neuropathy; drug synthesis; ibuprofen; dyspnea; coughing; nausea and vomiting; liver cirrhosis; hepatitis B; hemolytic anemia; malaise; lactic acidosis; disease transmission; bone marrow suppression; drug fever; dizziness; drug eruption; osteomalacia; antiviral activity; peginterferon alpha2a; peginterferon alpha2b; rigor; treatment contraindication; adefovir dipivoxil; Hepatitis B virus; treatment response; emtricitabine; entecavir; nucleoside analog; tenofovir; virus replication; highly active antiretroviral therapy; decompensated liver cirrhosis; bone density; chill; treatment duration; hepatomegaly; immunomodulation; liver carcinoma; bedtime dosage; hepatitis B(e) antigen; telbivudine; mixed infection; adefovir; antiviral resistance; peginterferon alpha; telaprevir; hepatitis B surface antigen; Fanconi renotubular syndrome; boceprevir; incivek; victrelis